{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:47:06Z","timestamp":1791996426219,"version":"4.4.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1093\/jnci\/djag331","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T11:52:54Z","timestamp":1789127574000},"source":"Crossref","is-referenced-by-count":0,"title":["Is it time to retire bolus cisplatin? Lessons from the ConCERT trial"],"prefix":"10.1093","author":[{"given":"Ross D","family":"Merkin","sequence":"first","affiliation":[{"name":"Mass General Brigham Cancer Institute , Boston, MA,","place":["United States"]},{"name":"Department of Medicine, Massachusetts General Hospital , Boston, MA,","place":["United States"]},{"name":"Massachusetts Eye and Ear , Boston, MA,","place":["United States"]},{"name":"Department of Medicine, Harvard Medical School , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0491-4454","authenticated-orcid":false,"given":"Aarti","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (Medical Oncology), Yale School of Medicine and Yale Cancer Center , New Haven, CT,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"2026101412115799800_djag331-B1","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1002\/1097-0142(19901101)66:9<1861::AID-CNCR2820660902>3.0.CO;2-I","article-title":"Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Long-term results of the Radiation Therapy Oncology Group study 81-17","volume":"66","author":"Marcial","year":"1990","journal-title":"Cancer"},{"key":"2026101412115799800_djag331-B2","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother Oncol"},{"key":"2026101412115799800_djag331-B3","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1200\/JCO.2007.14.8841","article-title":"Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis","volume":"26","author":"Machtay","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026101412115799800_djag331-B4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S1470-2045(10)70290-4","article-title":"Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial","volume":"12","author":"Nutting","year":"2011","journal-title":"Lancet Oncol"},{"key":"2026101412115799800_djag331-B5","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1634\/theoncologist.2017-0015","article-title":"Weekly low-dose versus three-weekly high-dose cisplatin for concurrent chemoradiation in locoregionally advanced non-nasopharyngeal head and neck cancer: a systematic review and meta-analysis of aggregate data","volume":"22","author":"Szturz","year":"2017","journal-title":"Oncologist"},{"key":"2026101412115799800_djag331-B6","doi-asserted-by":"publisher","first-page":"628","DOI":"10.7326\/0003-4819-95-5-628","article-title":"Renal and electrolyte disturbances associated with cisplatin","volume":"95","author":"Blachley","year":"1981","journal-title":"Ann Intern Med"},{"key":"2026101412115799800_djag331-B7","doi-asserted-by":"publisher","first-page":"103161","DOI":"10.1016\/j.eclinm.2025.103161","article-title":"Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice","volume":"82","author":"Sandhu","year":"2025","journal-title":"EClinicalMedicine"},{"key":"2026101412115799800_djag331-B8","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1200\/JCO.21.01293","article-title":"Weekly cisplatin plus radiation for postoperative head and neck cancer (JCOG1008): a multicenter, noninferiority, phase II\/III randomized controlled trial","volume":"40","author":"Kiyota","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026101412115799800_djag331-B9","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1200\/JCO.2017.74.9457","article-title":"Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial","volume":"36","author":"Noronha","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026101412115799800_djag331-B10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1200\/JCO.21.01752","article-title":"Phase II randomized trial of transoral surgery and low-dose intensity modulated radiation therapy in resectable p16+ locally advanced oropharynx cancer: an ECOG-ACRIN Cancer Research Group trial (E3311)","volume":"40","author":"Ferris","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026101412115799800_djag331-B11","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1200\/JCO.20.03128","article-title":"Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002)","volume":"39","author":"Yom","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026101412115799800_djag331-B12","doi-asserted-by":"publisher","first-page":"115343","DOI":"10.1016\/j.ejca.2025.115343","article-title":"Radiation vs. trans-oral surgery for treatment de-escalation in HPV-related oropharyngeal cancers: primary analysis of the ORATOR2 randomized trial","volume":"220","author":"Palma","year":"2025","journal-title":"Eur J Cancer"},{"key":"2026101412115799800_djag331-B13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djag276","article-title":"Concurrent chemotherapy and external radiation therapy (ConCERT): phase III noninferiority RCT of weekly vs. three weekly cisplatin in LA HNSCC","author":"Sharma","year":"2026","journal-title":"J Natl Cancer Inst"},{"key":"2026101412115799800_djag331-B14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(18)32779-X","article-title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial","volume":"393","author":"Gillison","year":"2019","journal-title":"Lancet"},{"key":"2026101412115799800_djag331-B15","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0140-6736(18)32752-1","article-title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial","volume":"393","author":"Mehanna","year":"2019","journal-title":"Lancet"},{"key":"2026101412115799800_djag331-B16","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.ijrobp.2021.04.015","article-title":"Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk HPV-associated oropharyngeal cancer (TROG 12.01) - A Trans-Tasman Radiation Oncology Group Study","volume":"111","author":"Rischin","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026101412115799800_djag331-B17","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1200\/JCO.2013.53.5633","article-title":"Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522","volume":"32","author":"Ang","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026101412115799800_djag331-B18","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1001\/jamaoncol.2023.3809","article-title":"Radiotherapy plus cisplatin with or without lapatinib for non-human papillomavirus head and neck carcinoma: a phase 2 randomized clinical trial","volume":"9","author":"Wong","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026101412115799800_djag331-B19","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S1470-2045(20)30737-3","article-title":"Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026101412115799800_djag331-B20","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S1470-2045(24)00100-1","article-title":"Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial","volume":"25","author":"Machiels","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026101412115799800_djag331-B21","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.1200\/JCO-25-00272","article-title":"Xevinapant or placebo plus platinum-based chemoradiotherapy in unresected locally advanced squamous cell carcinoma of the head and neck (TrilynX): a randomized, phase III study","volume":"43","author":"Bourhis","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026101412115799800_djag331-B22","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S0140-6736(25)01850-1","article-title":"Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial","volume":"407","author":"Bourhis","year":"2026","journal-title":"Lancet"},{"key":"2026101412115799800_djag331-B23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1056\/NEJMoa2415434","article-title":"Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer","volume":"393","author":"Uppaluri","year":"2025","journal-title":"N Engl J Med"},{"key":"2026101412115799800_djag331-B24","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1080\/14796694.2026.2619653","article-title":"JADE: phase 3 study of sequential dostarlimab post chemoradiotherapy in patients with locally advanced unresected HNSCC","volume":"22","author":"Siu","year":"2026","journal-title":"Future Oncol"},{"key":"2026101412115799800_djag331-B25","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1001\/jamaoncol.2024.1530","article-title":"Neoadjuvant nivolumab plus chemotherapy followed by response-adaptive therapy for HPV+ oropharyngeal cancer: OPTIMA II phase 2 open-label nonrandomized controlled trial","volume":"10","author":"Rosenberg","year":"2024","journal-title":"JAMA Oncol"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag331\/71947820\/djag331.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djag331\/71947820\/djag331.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:12:05Z","timestamp":1791994325000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article\/doi\/10.1093\/jnci\/djag331\/8916556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":25,"URL":"https:\/\/doi.org\/10.1093\/jnci\/djag331","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"article-number":"djag331"}}